Robert Carey

Robert F.
Carey was the founder of ACELYRIN, Inc., founded in 2020, where the title held was Chief Operating Officer & Director from 2020 to 2022.
Current jobs include Chairman at Beyond Air, Inc. since 2019; Independent Director at Sangamo Therapeutics, Inc. since 2016; Director at Hawthorne Race Course, Inc.; Lead Independent Director at Cour Pharmaceuticals Development Co., Inc. since 2023; Director at Beyond Air Ltd. since 2019; Director at Red Hen Corp.; Director at Suburban Downs, Inc.; and Director at Beyond Cancer, Ltd. Former jobs include Chief Executive Officer at Dresdner Kleinwort Wasserstein; Managing Director at Citizens JMP Securities LLC from 2003 to 2014; Independent Director at Argos Therapeutics, Inc. from 2014 to 2018; Independent Director at FS Development Corp.
from 2020 to 2021; Managing Director at Vector Securities International, Inc. from 1998 to 2001; Director at Illinois Biotechnology Industry Organization; Director at InStadium, Inc.; Director at Gemini Therapeutics, Inc. from 2020 to 2021; Chief Business Officer & Executive Vice President at Hyperion Therapeutics, Inc.; Chief Business Officer & Executive Vice President at Horizon Therapeutics Ltd. (Ireland) from 2014 to 2019; Principal at Shearson Lehman Hutton, Inc.; Principal at Ernst & Whinney; and Chief Business Officer & Executive Vice President at Horizon Pharma, Inc. from 2014 to 2019.
Education includes an undergraduate degree from the University of Notre Dame, conferred in 1981.